On-Demand

Guiding Light: Oncology Nurses’ Vital Role in Supporting Patients Through CLL Therapy

More than 200,000 people in the United States are living with a chronic lymphocytic leukemia (CLL) diagnosis, and it is responsible for approximately 4,410 U.S. deaths each year. The treatment landscape for CLL has changed dramatically…

Cancer-Associated VTE: Balancing Risk and Reward with Modern Anticoagulation

Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs).  Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the…

The Ever-Changing Options for the Treatment of CLL

The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a…

Meeting Complex Challenges in Proteinuric Glomerular Disease: An Expert Review of Emerging Data and Novel Therapeutics for IgA Nephropathy

This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics…

Efficacy and Safety of Asparaginase-Containing Treatment Regimens in ALL/LBL and Beyond – An Interactive Review for Oncology Nurses and Nurse Practitioners

This CEC Oncology ONS Chapters Series is targeted to oncology nurses and advanced nurse practitioners serving as part of an interprofessional healthcare team providing care for pediatric and adult patients with acute lymphoblastic leukemia (ALL) and…